Fibrosis in systemic sclerosis: Common and unique pathobiology

Fibrogenesis and Tissue Repair

Volumn 5, Issue SUPPL.1, 2012, Pages

  Bhattacharyya, Swati ^a   Wei, Jun ^a   Tourtellotte, Warren G ^a   Hinchcliff, Monique ^a   Gottardi, Cara G ^a   Varga, John ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BETA CATENIN; EARLY GROWTH RESPONSE FACTOR 1; GLITAZONE DERIVATIVE; IMATINIB; INNATE IMMUNE RECEPTOR; LYSOPHOSPHATIDIC ACID; MICRORNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE; RECEPTOR; ROSIGLITAZONE; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; WNT PROTEIN;

ARTICLE; AUTOIMMUNITY; BONE MARROW; CELL ACTIVATION; CELL DIFFERENTIATION; CELL FATE; CELL TYPE; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG MECHANISM; DRUG TARGETING; EPIGENETICS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROSIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INNATE IMMUNITY; LIGAND BINDING; LUNG FIBROSIS; MESENCHYMAL STEM CELL; MICROARRAY ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN FIBROBLAST; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; TISSUE INJURY; TRANSCRIPTION REGULATION;

EID: 84881010975     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-5-S1-S18     Document Type: Article

References (46)

1. Leroy EC. Connective tissue synthesis by scleroderma skin fibroblasts in cell culture. J Exp Med 1972, 135:1351-1362. 10.1084/jem.135.6.1351, 2139167, 4260235.
2. LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974, 54:880-889. 10.1172/JCI107827, 301627, 4430718.
3. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007, 117:557-567. 10.1172/JCI31139, 1804347, 17332883.
4. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005, 26:587-595. 10.1016/j.it.2005.09.004, 16168711.
5. Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events. Ann Med 2007, 39:42-53. 10.1080/07853890601098152, 17364450.
6. Beutler BA. TLRs and innate immunity. Blood 2009, 113:1399-1407. 2644070, 18757776.
7. Matsumoto M, Seya T. TLR3: interferon induction by double-stranded RNA including poly(I:C). Adv Drug Deliv Rev 2008, 60:805-812. 10.1016/j.addr.2007.11.005, 18262679.
8. Noble PW. Hyaluronan and its catabolic products in tissue injury and repair. Matrix Biol 2002, 21:25-29. 10.1016/S0945-053X(01)00184-6, 11827789.
9. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, Schwabe RF. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007, 13:1324-1332. 10.1038/nm1663, 17952090.
10. Whitfield ML, Finlay DR, Murray JI, Troyanskaya OG, Chi JT, Pergamenschikov A, McCalmont TH, Brown PO, Botstein D, Connolly MK. Systemic and cell type-specific gene expression patterns in scleroderma skin. Proc Natl Acad Sci USA 2003, 100:12319-12324. 10.1073/pnas.1635114100, 218756, 14530402.
11. Gardner H, Shearstone JR, Bandaru R, Crowell T, Lynes M, Trojanowska M, Pannu J, Smith E, Jablonska S, Blaszczyk M, et al. Gene profiling of scleroderma skin reveals robust signatures of disease that are imperfectly reflected in the transcript profiles of explanted fibroblasts. Arthritis Rheum 2006, 54:1961-1973. 10.1002/art.21894, 16736506.
12. Sargent JL, Milano A, Bhattacharyya S, Varga J, Connolly MK, Chang HY, Whitfield ML. A TGFbeta-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J Invest Dermatol 2010, 130:694-705. 10.1038/jid.2009.318, 19812599.
13. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316. 524221, 15520863.
14. Bhattacharyya S, Ishida W, Wu M, Wilkes M, Mori Y, Hinchcliff M, Leof E, Varga J. A non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 2009, 28:1285-1297. 10.1038/onc.2008.479, 19151753.
15. Distler JH, Jungel A, Huber LC, Schulze-Horsel U, Zwerina J, Gay RE, Michel BA, Hauser T, Schett G, Gay S, Distler O. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007, 56:311-322. 10.1002/art.22314, 17195235.
16. Bhattacharyya S, Wu M, Fang F, Tourtellotte W, Feghali-Bostwick C, Varga J. Early growth response transcription factors: key mediators of fibrosis and novel targets for anti-fibrotic therapy. Matrix Biol 2011, 30:235-242. 10.1016/j.matbio.2011.03.005, 3135176, 21511034.
17. Chen SJ, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y, Varga J. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006, 281:21183-21197. 10.1074/jbc.M603270200, 16702209.
18. Bhattacharyya S, Chen SJ, Wu M, Warner-Blankenship M, Ning H, Lakos G, Mori Y, Chang E, Nihijima C, Takehara K, et al. Smad-independent transforming growth factor-beta regulation of early growth response-1 and sustained expression in fibrosis: implications for scleroderma. Am J Pathol 2008, 173:1085-1099. 10.2353/ajpath.2008.080382, 2543076, 18772333.
19. Bhattacharyya S, Sargent JL, Du P, Lin S, Tourtellotte WG, Takehara K, Whitfield ML, Varga J. Egr-1 induces a profibrotic injury/repair gene program associated with systemic sclerosis. PLoS One 2011, 6:e23082. 10.1371/journal.pone.0023082, 3172216, 21931594.
20. Wu M, Melichian DS, de la Garza M, Gruner K, Bhattacharyya S, Barr L, Nair A, Shahrara S, Sporn PH, Mustoe TA, et al. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol 2009, 175:1041-1055. 10.2353/ajpath.2009.090241, 2731123, 19679873.
21. Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet 2004, 5:691-701. 10.1038/nrg1427, 15372092.
22. Vlad A, Rohrs S, Klein-Hitpass L, Muller O. The first five years of the Wnt targetome. Cell Signal 2008, 20:795-802. 10.1016/j.cellsig.2007.10.031, 18160255.
23. Selman M, Pardo A, Kaminski N. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs?. PLoS Med 2008, 5:e62. 10.1371/journal.pmed.0050062, 2265304, 18318599.
24. Konigshoff M, Eickelberg O. WNT signaling in lung disease: a failure or a regeneration signal?. Am J Respir Cell Mol Biol 2010, 42:21-31. 10.1165/rcmb.2008-0485TR, 19329555.
25. Chilosi M, Poletti V, Zamo A, Lestani M, Montagna L, Piccoli P, Pedron S, Bertaso M, Scarpa A, Murer B, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol 2003, 162:1495-1502. 10.1016/S0002-9440(10)64282-4, 1851206, 12707032.
26. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, Jahn A, Rose F, Fink L, Seeger W, Schaefer L, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest 2009, 119:772-787. 2662540, 19287097.
27. Bayle J, Fitch J, Jacobsen K, Kumar R, Lafyatis R, Lemaire R. Increased expression of Wnt2 and SFRP4 in Tsk mouse skin: role of Wnt signaling in altered dermal fibrillin deposition and systemic sclerosis. J Invest Dermatol 2008, 128:871-881. 10.1038/sj.jid.5701101, 17943183.
28. Beyer C, Schramm A, Akhmetshina A, Dees C, Kireva T, Gelse K, Sonnylal S, de Crombrugghe B, Taketo MM, Distler O, et al. beta-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis. Ann Rheum Dis 2012,
29. Lam AP, Flozak AS, Russell S, Wei J, Jain M, Mutlu GM, Budinger GR, Feghali-Bostwick CA, Varga J, Gottardi CJ. Nuclear {beta}-catenin is Increased in SSc Pulmonary Fibrosis and Promotes Lung Fibroblast Migration and Proliferation. Am J Respir Cell Mol Biol 2011,
30. Wei J, Fang F, Lam AP, Sargent JL, Hamburg E, Hinchcliff ME, Gottardi CJ, Atit R, Whitfield ML, Varga J. Wnt/beta-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum 2012,
31. Wei J, Melichian D, Komura K, Hinchcliff M, Lam AP, Lafyatis R, Gottardi CJ, MacDougald OA, Varga J. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: a novel mouse model for scleroderma?. Arthritis Rheum 2011, 63:1707-1717. 10.1002/art.30312, 3124699, 21370225.
32. Huang SK, Peters-Golden M. Eicosanoid lipid mediators in fibrotic lung diseases: ready for prime time?. Chest 2008, 133:1442-1450. 2582216, 18574287.
33. Oga T, Matsuoka T, Yao C, Nonomura K, Kitaoka S, Sakata D, Kita Y, Tanizawa K, Taguchi Y, Chin K, et al. Prostaglandin F(2alpha) receptor signaling facilitates bleomycin-induced pulmonary fibrosis independently of transforming growth factor-beta. Nat Med 2009, 15:1426-1430. 10.1038/nm.2066, 19966781.
34. Tager AM, LaCamera P, Shea BS, Campanella GS, Selman M, Zhao Z, Polosukhin V, Wain J, Karimi-Shah BA, Kim ND, et al. The lysophosphatidic acid receptor LPA1 links pulmonary fibrosis to lung injury by mediating fibroblast recruitment and vascular leak. Nat Med 2008, 14:45-54. 10.1038/nm1685, 18066075.
35. Xu MY, Porte J, Knox AJ, Weinreb PH, Maher TM, Violette SM, McAnulty RJ, Sheppard D, Jenkins G. Lysophosphatidic acid induces alphavbeta6 integrin-mediated TGF-beta activation via the LPA2 receptor and the small G protein G alpha(q). Am J Pathol 2009, 174:1264-1279. 10.2353/ajpath.2009.080160, 2671359, 19147812.
36. Ghosh AK, Bhattacharyya S, Lakos G, Chen SJ, Mori Y, Varga J. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum 2004, 50:1305-1318. 10.1002/art.20104, 15077315.
37. Ghosh AK, Bhattacharyya S, Wei J, Kim S, Barak Y, Mori Y, Varga J. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J 2009, 23:2968-2977. 10.1096/fj.08-128736, 2735362, 19395477.
38. Ferguson HE, Kulkarni A, Lehmann GM, Garcia-Bates TM, Thatcher TH, Huxlin KR, Phipps RP, Sime PJ. Electrophilic peroxisome proliferator-activated receptor-gamma ligands have potent antifibrotic effects in human lung fibroblasts. Am J Respir Cell Mol Biol 2009, 41:722-730. 10.1165/rcmb.2009-0006OC, 2784409, 19286977.
39. Wu M, Melichian DS, Chang E, Warner-Blankenship M, Ghosh AK, Varga J. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol 2009, 174:519-533. 10.2353/ajpath.2009.080574, 2630560, 19147827.
40. Tan X, Dagher H, Hutton CA, Bourke JE. Effects of PPAR gamma ligands on TGF-beta1-induced epithelial-mesenchymal transition in alveolar epithelial cells. Respir Res 2010, 11:21. 10.1186/1465-9921-11-21, 2844370, 20178607.
41. Kapoor M, McCann M, Liu S, Huh K, Denton CP, Abraham DJ, Leask A. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum 2009, 60:2822-2829. 10.1002/art.24761, 19714649.
42. Karnik P, Tekeste Z, McCormick TS, Gilliam AC, Price VH, Cooper KD, Mirmirani P. Hair follicle stem cell-specific PPARgamma deletion causes scarring alopecia. J Invest Dermatol 2009, 129:1243-1257. 10.1038/jid.2008.369, 3130601, 19052558.
43. Ye P, Zhang XJ, Wang ZJ, Zhang C. Effect of aging on the expression of peroxisome proliferator-activated receptor gamma and the possible relation to insulin resistance. Gerontology 2006, 52:69-75. 10.1159/000090951, 16508313.
44. Wei J, Ghosh AK, Sargent JL, Komura K, Wu M, Huang QQ, Jain M, Whitfield ML, Feghali-Bostwick C, Varga J. PPARgamma downregulation by TGFss in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One 2010, 5:e13778. 10.1371/journal.pone.0013778, 2970611, 21072170.
45. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 2011, 10:267-275. 10.1016/j.autrev.2010.09.015, 20863909.
46. Bhattacharyya S, Wei J, Varga J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat Rev Rheumatol 2012, 8:42-54.